妇可靖胶囊治疗慢性盆腔炎大鼠疗效及其作用机制研究

Effects of Fukejing Capsule on Chronic Pelvic Inflammatory Rats and Its Mechanism

目的通过妇可靖胶囊(FKJC)干预慢性盆腔炎(chronic pelvic inflammatory disease, CPID)模型大鼠,观察FKJC对CPID大鼠的治疗作用,并从形态学、病理学、分子生物学层面,对其可能的作用机制进行初步探讨,为FKJC的临床推广应用提供理论依据。方法 65只SD雌性大鼠随机抽取10只为空白对照组,造模15 d后随机抽取5只模型大鼠进行形态学和病理学观察用于模型验证,造模成功后,随机分为模型组(n=10)、坤复康胶囊组(n=10)、FKJC低、中、高剂量组(n=10)。空白对照组和模型组灌服蒸馏水,其余各组分别灌胃给药,1次/d,持续28d。每天观察大鼠情况,每7d测量大鼠体重。末次给药后,禁食不禁水12 h,处理动物。腹主动脉中收集血液,切除子宫组织。ELASA法检测血清中1L-1β和TNF-α水平,蛋白免疫印迹(WB)法检测子宫组织中FGF-2、IGF-1蛋白表达水平。结果造模15 d后模型大鼠的观察结果符合CPID病理特征,表明模型建立成功。治疗后,各治疗组血清中1L-1β及TNF-α的含量相比于模型组均下降(p<0.05)。子宫大体形态观察,模型组宫腔缩小,子宫内膜充血,骨盆黏连;各治疗组均较模型组有所好转。WB蛋白表达趋势显示模型组子宫组织FGF-2、IGF-1蛋白表达增加,经药物干预后,FKJC高、中剂量组FGF-2、IGF-1的蛋白表达量较模型组减少(p<0.05),且这种变化趋势在FKJC各剂量组表现出剂量依赖性,剂量越大,变化越明显。结论 FKJC可以明显改善慢性盆腔炎大鼠病理症状,这可能与其抑制炎性介质1L-1β和TNF-α的释放及下调子宫FGF-2、IGF-1的蛋白表达有着密切的关系。

Objective To observe the therapeutic effect of Fukejing Capsule(FKJC) on the rats with chronic pelvic inflammatory disease(CPID), and to explore the possible mechanism of FKJC from the aspects of morphology, pathology and molecular biology, and provide theoretical basis for the clinical application of FKJC. Methods 65 SD female rats were randomly divided into blank control group(sham operation group, n=10). After 15 days of model making, 5 rats were randomly selected for morphological and pathological observation for model verification. After the model was successfully established, they were randomly divided into model group(n=10), Kunfukang capsule group(n=10), FKJC low, medium and high dose group(n=10). The blank control group and model group were given distilled water, and the rest groups were given the medicine once a day for 28 days. Observe the rat every day and measure the weight every 7 days. Blood was collected from abdominal aorta and uterus was removed. The levels of 1 L-1 β and TNF-α in serum were detected by ELISA, and the expression levels of FGF-2 and IGF-1 in uterus were detected by Western blot(WB). Results The results of the model rats were in accordance with the pathological characteristics of CPID 15 days after the model was established, which indicated that the model was successfully established. After the treatment, the levels of 1 L-1 β and TNF-α in serum of each treatment group were lower than those in the model group(p< 0.05). The uterus morphology was observed, the uterine cavity in the model group was reduced, the endometrium was congested and the pelvis was attached. After administration, the treatment group was better than the model group. WB protein expression trend showed that the expression of FGF-2 and IGF-1 in uterus tissue of model group increased. After the intervention of drug, the protein expression of FGF-2 and IGF-1 in FKJC high and medium dose group was lower than that in model group(p< 0.05). The change trend showed dose dependence in FKJC dose group, the greater the dose, the more obvious the change. Conclusion FKJC can improve the pathological symptoms of chronic pelvic inflammatory rats. It may be closely related to the inhibition of the release of inflammatory media 1 L-1 β and TNF-α and down regulation of the expression of FGF-2 and IGF-1 in uterus.